USANA Health Sciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Equity-Based Compensation (Tables)

9 Months Ended

Sep. 27, 2014



2014		$ 2,388
2015		7,388
2016		5,622
2017		3,516
2018+		724
		$ 19,638

The cost above is expected to be recognized over a weighted-average
period of 2.0 years.



	Nine Months Ended
	September 28,	September 27,
	2013	2014

Expected volatility (1)	42.5%	40.0%
Risk-free interest rate (2)	0.7%	1.2%
Expected life (3)	3.95 yrs	3.55 yrs
Expected dividend yield (4)	0.0%	0.0%
Weighted-average exercise price (5)	$ 48.26	$ 58.04

(1) The Company utilizes historical volatility of the trading price of its common stock.
(2) Risk-free interest rate is based on the U.S. Treasury yield curve with respect to the expected life of
the award.
(3) Depending upon the terms of the award, one of two methods will be used to calculate expected life: (i)
a weighted-average that includes historical settlement data of the Company’s equity awards and a
hypothetical holding period, or (ii) the simplified method.
(4) The Company historically has not paid dividends.
(5) Exercise price is the closing price of the Company's common stock on the date of grant.


	Shares	Weighted-average exercise price	Weighted-average remaining contractual term	Aggregate intrinsic value*
Outstanding at December 28, 2013	1,827	$ 37.37	2.6	$ 74,160
Granted	711	58.04
Exercised	(434)	32.33
Forfeited	(48)	37.25
Expired	-	-

Outstanding at September 27, 2014	2,056	$ 45.58	2.7	$ 54,978

Exercisable at September 27, 2014	526	$ 38.37	1.4	$ 17,743

* Aggregate intrinsic value is defined as the difference between the current market value at the reporting date (the closing price of the
Company's common stock on the last trading day of the period) and the exercise price of awards that were in-the-money. The
closing price of the Company's common stock at December 28, 2013, and September 27, 2014, was $77.72 and $71.98, respectively.